Evidence for pyroptosis in I/R injury comes from studies with caspase-1 inhibitors, which reduce cardiac I/R injury 36 and the IL-1β inhibitor, Canakinumab, which in humans has shown to result in a 15% reduction in mortality associated with all cause cardiovascular disease.37 Here, CASP1 is linked to cardiovascular disorder.